Novel Resveratrol and 5-Fluorouracil Coencapsulated in PEGylated Nanoliposomes Improve Chemotherapeutic Efficacy of Combination against Head and Neck Squamous Cell Carcinoma

Table 2

Optimization of encapsulation efficiency for liposomal 5-FU.

Drug : lipid ratio (w/w)	Encapsulation efficiency (%)
1 : 1	3.56±1.20^a
2 : 5	3.20±0.66^a
4 : 5	3.73±0.51^a
1 : 10	4.00±0.58^a
1 : 20	14.76±3.33
1 : 30	9.68±2.32
1 : 40 : 8*	5.29±0.06^b
1 : 20 : 1*	15.52±0.92
1 : 40 : 1*	9.31±0.63^b
1 : 40 : 2*	15.25±0.15
1 : (18 : 2)**	5.81±0.95^c
1 : 1 : (18 : 2)***	24.63±1.46

adenotes that the groups are significantly different from the 1 : 20 ratio (𝑃<0.05).
bdenotes that the groups are significantly different from the 1 : 40 : 2 ratio (𝑃<0.05).
cdenotes that the groups are significantly different from the 1 : 1 : (18 : 2) ratio (𝑃<0.05).
*denotes 5-FU : EPC : Res (dual encapsulated formulation without DSPE-PEG).
**denotes 5-FU : EPC : DSPE-PEG (PEGylated 5-FU formulation).
***denotes 5-FU : Res : EPC : DSPE-PEG (PEGylated dual liposomal formulation).